Table 1.
Characteristics of myopia randomized controlled trials
| Trial Characteristics | N | Percentage |
|---|---|---|
| Publication Year | ||
| 2019 | 6 | 8.2% |
| 2020 | 10 | 13.7% |
| 2021 | 12 | 16.4% |
| 2022 | 23 | 31.5% |
| 2023 | 22 | 30.1% |
| Journal | ||
| Ophthalmology | 7 | 9.6% |
| JAMA Ophthalmology | 5 | 6.8% |
| American Journal of Ophthalmology | 4 | 5.5% |
| Scientific Reports | 4 | 5.5% |
| Acta Ophthalmology | 3 | 4.1% |
| BMC Ophthalmology | 3 | 4.1% |
| British Journal of Ophthalmology | 3 | 4.1% |
| Contact Lens Anterior Eye | 3 | 4.1% |
| Journal of Refractive Surgery | 3 | 4.1% |
| Ophthalmic and Physiological Optics | 3 | 4.1% |
| Translational Vision Science and Technology | 3 | 4.1% |
| Current Eye Research | 2 | 2.7% |
| Eye and Contact Lens | 2 | 2.7% |
| Indian Journal of Ophthalmology | 2 | 2.7% |
| International Ophthalmology | 2 | 2.7% |
| Journal of Clinical Medicine | 2 | 2.7% |
| Journal of Ophthalmology | 2 | 2.7% |
| JAMA | 2 | 2.7% |
| Asia-Pacific Journal of Ophthalmology | 1 | 1.4% |
| Clinical and Experimental Ophthalmology | 1 | 1.4% |
| Clinical and Experimental Optometry | 1 | 1.4% |
| Graefe’s Archive for Clinical and Experimental Ophthalmology | 1 | 1.4% |
| International Journal of Medical Sciences | 1 | 1.4% |
| International Journal of Ophthalmology | 1 | 1.4% |
| International Journal of Pharmaceutical and Clinical Research | 1 | 1.4% |
| International Journal of Research in Ayurveda and Pharmacy | 1 | 1.4% |
| Journal of Ocular Pharmacology and Therapeutics | 1 | 1.4% |
| Journal of the Pakistan Medical Association | 1 | 1.4% |
| Journal of Personalized Medicine | 1 | 1.4% |
| JAMA Open Network | 1 | 1.4% |
| JAMA Pediatrics | 1 | 1.4% |
| Japan Journal of Ophthalmology | 1 | 1.4% |
| Ophthalmic Epidemiology | 1 | 1.4% |
| Optometry and Vision Science | 1 | 1.4% |
| Saudi Journal of Ophthalmology | 1 | 1.4% |
| Technology and Health Care | 1 | 1.4% |
| Intervention | ||
| Atropine | 19 | 26.0% |
| 0.01% Atropine | 12 | |
| 0.05% Atropine | 1 | |
| Different Atropine Concentrations | 6 | |
| Combined Treatments | 10 | 13.7% |
| Lens | 22 | 30.1% |
| Orthokeratology | 7 | |
| Other lens | 15 | |
| Light Therapy | 8 | 11.0% |
| Social Intervention | 3 | 4.1% |
| Supplement | 2 | 2.7% |
| Surgery | 9 | 12.3% |
| Lasik vs. SMILE | 5 | |
| PRK vs. SMILE | 1 | |
| PRK vs. LASIK | 1 | |
| LASIK with accelerated cross-linking | 2 | |
| Country of the Trial | ||
| China | 37 | 50.7% |
| Hong Kong | 8 | 11.0% |
| India | 6 | 8.2% |
| Japan | 4 | 5.5% |
| United States | 4 | 5.5% |
| Denmark | 2 | 2.7% |
| Multiple countries | 2 | 2.7% |
| Singapore | 2 | 2.7% |
| Brazil | 1 | 1.4% |
| Egypt | 1 | 1.4% |
| Malaysia | 1 | 1.4% |
| Australia | 1 | 1.4% |
| Germany | 1 | 1.4% |
| Israel | 1 | 1.4% |
| Spain | 1 | 1.4% |
| Vietnam | 1 | 1.4% |
| Nationality of Corresponding Authors | ||
| China | 36 | 49.3% |
| Hong Kong | 8 | 11.0% |
| India | 6 | 8.2% |
| United States | 4 | 5.5% |
| Japan | 4 | 5.5% |
| Australia | 2 | 2.7% |
| Singapore | 2 | 2.7% |
| Multiple countries | 2 | 2.7% |
| Denmark | 2 | 2.7% |
| Brazil | 1 | 1.4% |
| Egypt | 1 | 1.4% |
| Germany | 1 | 1.4% |
| Malaysia | 1 | 1.4% |
| Israel | 1 | 1.4% |
| Spain | 1 | 1.4% |
| Vietnam | 1 | 1.4% |
| Funding source | ||
| Government only | 23 | 31.5% |
| Industry only | 14 | 19.2% |
| Government and University | 12 | 16.4% |
| Industry and University | 4 | 5.5% |
| University only | 4 | 5.5% |
| Government and Industry | 3 | 4.1% |
| Organization | 3 | 4.1% |
| N/A | 10 | 13.7% |
| Number of arms | ||
| 2 | 54 | 74.0% |
| 3 | 12 | 16.4% |
| 4 | 5 | 6.8% |
| 5 or greater | 2 | 2.7% |
| Number of clinical centers | ||
| 1 | 49 | 67.1% |
| 2 | 7 | 9.6% |
| 3 or greater | 13 | 17.8% |
| Not provided | 4 | 5.5% |
| Trial registration | ||
| Registered | 53 | 72.6% |
| Not registered | 20 | 27.4% |
| Enrollment period (months) | ||
| Less than 6 months | 11 | 15.1% |
| 6–12 months | 8 | 11.0% |
| 13–18 months | 10 | 13.7% |
| 19–24 months | 4 | 5.5% |
| Greater than 24 months | 14 | 19.2% |
| Not given | 26 | 35.6% |